| Identification | Back Directory | [Name]
2H-Benzimidazol-2-one, 5-[[5-chloro-2-(2,2,6,6-tetramethyl-4-morpholinyl)-4-pyrimidinyl]amino]-1,3-dihydro-3-(3-hydroxy-3-methylbutyl)-1-methyl- | [CAS]
2253879-65-9 | [Synonyms]
BCL6-IN-4
2H-Benzimidazol-2-one, 5-[[5-chloro-2-(2,2,6,6-tetramethyl-4-morpholinyl)-4-pyrimidinyl]amino]-1,3-dihydro-3-(3-hydroxy-3-methylbutyl)-1-methyl- | [Molecular Formula]
C25H35ClN6O3 | [MDL Number]
MFCD33548856 | [MOL File]
2253879-65-9.mol | [Molecular Weight]
503.04 |
| Chemical Properties | Back Directory | [Boiling point ]
647.3±65.0 °C(Predicted) | [density ]
1.237±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 73.33 mg/mL (145.77 mM; Need ultrasonic) | [form ]
Solid | [pka]
15.14±0.29(Predicted) | [color ]
White to light brown |
| Hazard Information | Back Directory | [Biological Activity]
BCL6-IN-4 is a potent B-cell lymphoma 6 (BCL6) inhibitor with an IC50 of 97 nM. BCL6-IN-4 has anti-tumor activities[1].
BCL6-IN-4 (compound 25b) inhibits OCI-Ly1 and OCI-Ly3 cell lines growth with GI50 values of 2.8 μM and 4.2 μM, respectively[1]. | [References]
[1]. Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068. |
|
|